1[1]Shu Z, Li J. Fructose-1,6-diphosphate-added total parenteral n u trition in septic animals and stressed patients[J]. Chin Med J (Engl) (China) , 2001, 114(11) :51639～51645.
2[2]Borawski J, Pawlak K, Naumnik B, et al. Relations between oxidati ve stress, hepatocyte growth factor, and liver disease in hemodialysis patients [J]. Ren Fail, 2002, 24(6) :825～837.
3[3]Squadrito F, Sturniol O, Altavilla D, et al. Effect of fructose 1 ,6-diphosphate in treating fulminant hepatic failure[J].Resuscitation, 1989 ,18:299.
4[4]Borawski J, Mysliwiec M. Serum hepatocyte growth factor is associa ted with viral hepatitis, cardiovascular disease, erythropoietin treatment, and type of heparin in haemodialysis patients[J]. Nephrol Dial Transplant, 2002, 17(4) :637～644.
5[5]Taieb J, Delarche C, Paradis V, et al.Polymorphonuclear neutroph ils are a source of hepatocyte growth factor in patients with severe alcoholic h epatitis[J]. J Hepatol, 2002, 36(3):342～348.
8Yu L,Milton N,Groleau E G,et al. Existence of a mannitol hydrate during freeze-drying and practical implications[J].J Pharm Sci,1999,88(2) :196-198.
9Cannon A,Trappler E H. The influence of lyophilization on the polyrnorphic behavior of mannitol[J]. J Pharm Sci, 2000,89(1): 13-22.
10Arakawa T, Prestrelski S J, Kenney W C, et al. Factors affecting short-term and long-term stabilities of proteins [J]. Adv Drug Deliv Rev,2001, 46(1/3), 307-326.
